Ayugen Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.17 M
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -57.29%
- Profit Growth -128.72%
- Ebitda -106.59%
- Net Worth -9.75%
- Total Assets -21.41%
About Ayugen Biosciences
Ayugen Biosciences Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 June 2005 and has a history of 19 years and seven months. Its registered office is in Nagar, Pune - 411 005., Maharashtra.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.17 M, as per Ministry of Corporate Affairs (MCA) records.
Manish Pungliya and Sampat Pungliya serve as directors at the Company.
Company Details
- Location Nagar, Pune - 411 005., Maharashtra
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85199PN2005PTC020901
-
Company No.
020901
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Jun 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
What products or services does Ayugen Biosciences Private Limited offer?
Ayugen Biosciences Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Ayugen Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Pungliya
|
Director | 20-Jun-2005 | Current |
|
Sampat Pungliya
|
Director | 20-Jul-2006 | Current |
Financial Performance of Ayugen Biosciences.
Ayugen Biosciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 57.29% decrease. The company also saw a substantial fall in profitability, with a 128.72% decrease in profit. The company's net worth dipped by a decrease of 9.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ayugen Biosciences?
In 2023, Ayugen Biosciences had a promoter holding of 81.21% and a public holding of 18.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Genearche Wellness Private LimitedManish Pungliya is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ayugen Biosciences?
Unlock and access historical data on people associated with Ayugen Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ayugen Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ayugen Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
